Survodutide
GLP-1 and glucagon receptor dual agonist
A dual agonist studied for obesity and for metabolic dysfunction associated steatohepatitis endpoints.
How it works
Balanced GLP-1 and glucagon receptor activation reduces caloric intake while raising energy expenditure and driving hepatic lipid clearance.
What research has shown
Phase 2 literature reports about 19% weight reduction at 46 weeks and significant improvement in liver histology endpoints.
Reported ranges in the literature
Low end
0.6 mg weekly during titration
Optimal
3.6 mg weekly
High end
6.0 mg weekly, the top studied dose
Frequency reported in the literature: Once weekly
Protocol duration and pairing
Typical study duration
46 to 76 weeks in reported obesity and MASH programs.
Best paired with
Hepatic fat endpoints mean it is most often paired in research with mitochondrial compounds.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.